Four structured decision reviews. One connected system.
Is the disease biology signal strong enough to justify target exploration?
Which targets perform best within the disease context and criteria for investment?
Which preclinical models best recapitulate the relevant patient biology?
Does clinical data support advancing the program or refining the hypothesis?
Augment your in-house bioinformatics expertise with professional services from Pluto’s Scientific Insights team.
